department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

NELARABINE · pharmadog

pharmadog
drugs
NELARABINE

drug · small molecule

patient view →

NELARABINE

Marketedupdated 2mo ago

by $AMRX Amneal Pharmaceuticals, Inc.🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 6 investigational indications.

all catalysts(2)

approval · 2

NELARABINE — FDA approval

NELARABINE — FDA approval

News(0)

no news has mentioned this drug yet

brand

NELARABINE

trade names

Arranon, Atriance

generic

NELARABINE

MOA

12.1 Mechanism of Action Nelarabine is a prodrug of the deoxyguanosine analogue 9-β- D -arabinofuranosylguanine (ara-G), a nucleoside metabolic inhibitor. Nelarabine is demethylated by adenosine deaminase (ADA) to ara-G, mono-phosphorylated by deoxyguanosine kinase and deoxycytidine kinase, and subsequently converted to the active 5’-triphosphate, ara-GTP. Accumulation of ara-GTP in leukemic blasts allows for incorporation into deoxyribonucleic acid (DNA), leading to inhibition of DNA synthesis and cell death. Other mechanisms may contribute to the cytotoxic and systemic toxicity of nelarabine.

phase

marketed

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 59m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$AMRX16.92-1.34%

$AMRX16.92-1.34%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

tagApproval4 co-mentions · 2 sources
companyZydus Lifesciences Ltd2 co-mentions · 2 sources
tagRecall2 co-mentions · 2 sources

Trials studying NELARABINE

phase2Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)recruitingn=100
phase3Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescentsactive not recruitingn=560
phase3Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphomaactive not recruitingn=790
phase3The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphomanot yet recruitingn=83